Supporting Alzheimer’s Disease Diagnosis with Artificial Intelligence
MINT-AD
Multimodal Interpretable Transformer for Alzheimer's Disease.
Empower Clinical Excellence
MINT-AD leverages decades of international research in genomics, clinical practice, and cognitive science into a clinical decision support tool.
Patients
Families
MINT-AD brings world-class AI risk prediction and decision support directly into the hands of:
Physicians:
Accurate, individualized insights, even in regions with limited medical technology.
Researchers:
Multimodal data analysis to unlock new risk factors and understand disease progression.
Data Integration & Purpose
A comprehensive data integration allows MINT-AD to identify subtle changes and detect early patterns of cognitive decline.
Demographic
Location
Age
Gender
Living
Coditions
& other
socioeconomic
factors
Clinical History
Family History
Over 390
Medical Variables
Brain images
Magnetic
Resonance Imaging
PET
Computed
Tomography Scans
Omics Data
Genetics
Epigenetics
Specific
Biomarkers
Cognitive tests
Neuropsychological
Evaluations
Memory
Language
Attention
Why develop
MINT-AD
Reduces diagnostic delays in underserved areas with limited equipment.
Supports identification of at-risk patients and helps inform public health policy.
Reveals socio-economic and lifestyle combinations that impact Alzheimer’s progression.
Empowering Better Outcomes Through
Data-Driven Alzheimer’s Solutions
Evidence You Can Trust:
Interpretable, science-backed outputs with clarity around uncertainty.
Informed Recommendations, Personalized Outcomes:
Timely insights for underserved communities without complex infrastructure.
Seamless Integration for Deeper Discovery:
Multidimensional data reveals novel combinations of social, genetic, and lifestyle determinants.
Reduce inequality:
Designed for high accuracy, particularly in scenarios where false negatives are common.
Meet the leader behind MINT-AD
Other projects you may like
IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant”
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida’s Department of Psychiatry and Behavioral Neurosciences
